|
|

2007
Company Report

2007
Financial Report
|
|
| News...... |
|
|
|
| | | | | | | | | 15 June, 2009 | | NicOx : additional 24-hour blood pressure results for naproxcinod presented at the EuropeanMeeting on Hypertension | | | | | | | | | | | | | | | | | | | | | | | 12 June, 2009 | | NicOx presents naproxcinod results in several posters at EULAR | | | | | | | | | | | | | | | | | | | | | | | 09 June, 2009 | | NicOx publishes results of the ZEST phase 2 study for naproxcinod | | | | | | | | | | | | | | | | | | | | | |
| | Shareholder meetings of NicOx convened on second call for June 17, 2009 | | | | | | | | | |
| | Presentation
given by Michele Garufi, Chairman & CEO, and Eric Castaldi, Chief
Financial Officer, at the Shareholder meetings | | | | | | | | | | | | | | | | | | | | | | | 19 May, 2009 | | NicOx presents phase 3 quality of life data for naproxcinod at ISPOR | | | | | | | | | | | | | | | | | | | | | | | 13 May, 2009 | | NicOx reports first quarter 2009 financial results | | | | | | | | | |
|
|
|

|
| NicOx
is a product-driven biopharmaceutical company dedicated to the
development of nitric oxide-donating drugs for unmet medical needs. |
|
NicOx
is targeting the therapeutic areas of inflammatory and
cardiometabolic diseases.
|
|
| NicOx
aims to build itself into a self-sustaining, fully integrated
bio-pharmaceutical company. |
|
|
Nitric
Oxide
Knowledge Center |
 |
|
|